Kara N Maxwell, MD, PhD
Assistant Professor of Medicine (Hematology-Oncology)
Department: Medicine
Graduate Group Affiliations
Contact information
BRB Room 810
421 Curie Blvd
Philadelphia, PA 19104
421 Curie Blvd
Philadelphia, PA 19104
Publications
Education
BS (Genetics, Biochemistry)
University of Wisconsin-Madison, 1998.
PhD (Molecular and Cellular Biology)
Rockefeller University, 2006.
MD (Medicine)
Weill Cornell Medical College, 2007.
Permanent linkBS (Genetics, Biochemistry)
University of Wisconsin-Madison, 1998.
PhD (Molecular and Cellular Biology)
Rockefeller University, 2006.
MD (Medicine)
Weill Cornell Medical College, 2007.
Description of Clinical Expertise
cancer risk evaluation, breast cancer risk, hereditary breast ovarian cancer, Li Fraumeni Syndrome, Fanconi AnemiaDescription of Research Expertise
I am a Medical Oncologist with postdoctoral training in Cancer Genetics and PhD training in molecular and cellular biology. My research interests are in the genetics of human disease, particularly familial breast and prostate cancers, and in determinants of disease penetrance.Maxwell Lab
https://www.med.upenn.edu/kmaxwelllab/
We are a translational human genetics and genomics research laboratory studying mechanisms of tumor formation in inherited cancer syndromes. We have a focus on breast and prostate cancer, but are interested in the broad range of tumor types affected by DNA repair deficiency. We are using multi-omics analyses of human samples coupled with in vitro and in vivo modelling systems to understand how tumors form in patients with inherited cancers.
For our work in prostate cancer genetics, we leverage the resources of the Basser Center for BRCA (https://www.basser.org/), the Penn Medicine Biobank (https://www.itmat.upenn.edu/biobank/), the Veterans' Affairs and Prostate Cancer Foundation Partnership (https://www.pcf.org/va-partnership/) and the VA Million Veterans' Program (https://www.mvp.va.gov/). Dr. Maxwell is the Director of the Basser Center’s Men and BRCA program (https://www.basser.org/brca/brca-men).
We are actively involved in many aspects of basic, translational and clinical research in Li Fraumeni Syndrome, caused by germline TP53 disease causing variants. We are one of the founding members of the EDISYN consortium (https://www.edisyn.org/) to study early cancer detection in patients with Li Fraumeni Syndrome, and we are active participants in the LIFTUp study (https://liftupstudy.org/).
We take a multi-disciplinary approach, collaborating with our colleagues across basic science labs and the clinical arena. Our research is funded by the National Cancer Institute, the Veterans’ Affairs Office of Research amd Development, the Prostate Cancer Foundation, the Burroughs Wellcome Foundation, the Li Fraumeni Syndrome Association and the Basser Center for BRCA.
Contact us for more details on rotation and post-doc projects in the fields of:
- Prostate cancer genetics
- BRCA1/2 cancers in men
- Li Fraumeni Syndrome and TP53-related disorders
- Mutational signatures in Veteran tumors
Lab Members 2024-25:
Greg Kelly MS, Lab Manager
Caitlin Orr PhD, Penn Project Manager
Leslie Grush AuD, VA Project Manager
KJ Johnson, Lab Administrative Assistant
Heena Desai MS, Bioinformatician
Ryan Hausler MS, Bioninformatician
Renyta Moses, CAMB Cancer Biology PhD Student
Taylor Crawford, CAMB Cancer Biology PhD Student
Nabamita Boruah PhD, Postdoctoral Fellow
Anh Le DO, Medicine Intern
Maliha Tayeb, Clinical Research Coordinator
Michael Wang, Clinical Research Coordinator
Rosella Delgado, Genetic Counseling Assistant
Sophia Spiegel, Penn Medical Student
Jillian O'Toole, Penn MS GC Student
Selected Publications
Valle LF, Scobie M, Rowe K, Pritchard CC, Montgomery B, Garraway IP, Nickols NG, Schoen MW, Kishan AU, Kelley MJ, Rettig MB, Maxwell KN.: Interference of Clonal Hematopoiesis in cfDNA Liquid Biopsy Testing & Identification of Actionable Alterations in Large Diverse Cohort of US Veterans. Oncologist oyag265, Jul 2026 Notes: doi: 10.1093/oncolo/oyag265.Buckley KH, Dungan ME, Dinh K, Kelly GM, Hausler R, Bennett KE, Clay DG, Youngman JE, Majer AD, Beyries KA, Niccum BA, Shaffer SM, Karakasheva TA, Hamilton KE, Kochman ML, Ginsberg GG, Ahmad N, Maxwell KN, Katona BW: Gastric epithelium from BRCA1 and BRCA2 carriers harbors increased double-stranded DNA damage and augmented growth. Mol Cancer Res 24(7): 589-600, Jul 2026 Notes: doi: 10.1158/1541-7786.MCR-25-0970.
Schoen MW, Li J, Zeng S, Desai H, Hausler R, Haroldsen CL, Owens L, Valle LF, Etzoni RB, Rebbeck TR, Rose BS, Kelley MJ, Montgomery RB, Nickols NG, Rettig MB, Yamoah K, Maxwell KN, Garraway IP.: Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate. JCO Precis Oncol 10(7): e2600021, Jul 2026 Notes: doi: 10.1200/PO-26-00021.
Crawford TB, Tayeb M, Barrett E, Al-Saleem T, Kondam P, Hausler R, Symecko H, Orr C, Wolfe C, Mann D, Spielman K, Wong G, Haas N, Narayan V, Robinson K, Takvorian S, Wong YN, Sokolova A, Montgomery RB, Menendez C, Kelley MJ, Aiello LB, Garraway IP, Domchek SM, Maxwell KN: Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients. J Natl Compr Canc Netw 24(7): e267006, Jun 2026 Notes: doi: 10.6004/jnccn.2026.7006.
Pepin A, Doucette A, Narayan VK, Maxwell KN, Takvorian SU, O'Brien SR, Mankoff DA, Mulugeta PG, Taunk NK.: Differential Response to (177)Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 67(6): 926-928, Jun 2026 Notes: doi: 10.2967/jnumed.125.270757.
MacFarland SP, Goodman VE, King-Dowling S, Zelley K, Crompton BD, Schultz KAP, Maese LD, Maxwell KN, Khincha PP, Schwartz LA.: Liquid Biopsy for Cancer Screening in Li-Fraumeni Syndrome: Interest in Clinical Trial and Reported Barriers to Standard-of-Care Screening. Cancer Prev Res 19(6): 331-337, Jun 2026 Notes: doi: 10.1158/1940-6207.
Cheng HH, Maxwell KN, Salari K, Cooperberg MR, Follmer K, Jeter JM, Jun G, Lee DJ, Patel HD, Schaeffer EM, Sokolova AO, Wolff EM, Lin DW.: The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study. BJU Int Jun 2026 Notes: doi: 10.1111/bju.70334.
Moses R, Powers J, Levine AS, Garber JE, MacFarland SP, Rana HQ, Murphy ME, Maxwell KN.: The biology of hypomorphic TP53 variants and implications for clinical management. Clin Cancer Res Jun 2026 Notes: doi: 10.1158/1078-0432.
Buckley KH, Zhu Y, Dinh K, Hausler R, Gala R, Spiegel SR, Delgado R, Clay DG, Kelly GM, Brower J, Domchek SM, Maxwell KN, Katona BW.: Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers. Int J Cancer Jun 2026 Notes: doi: 10.1002/ijc.70572.
Xu G, Karunamuni R, Dornisch AM, Brunette CA, Danowski ME, Desai H, Dochtermann D, Garraway IP, Hauger RL, Kibel AS, Lynch JA, Pyarajan S, Rose BS, Teerlink CC, Andreassen OA, Dale AM, Donovan JL, Hamdy F, Kachuri L, Lane A, Martin RM, Mills IG, Neal DE, Turner EL, Witte JS, Schleutker J, Pashayan N, Batra J; Australian Prostate Cancer BioResource (APCB); Nordestgaard BG, Hamilton RJ, Wolk A, Albanes D, Atkins J, Blot WJ, Mucci LA, Nielsen SF, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Menegaux F, Park JY, MacInnis RJ, Rosenstein BS, Lu YJ, Watya S, Vega A; NC-LA PCaP Investigators; IMPACT Study Steering Committee and Collaborators; Kogevinas M, Wiklund F, Plym A, Teixeira MR, Multigner L, Leach RJ, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, Ost P, Razack A, Fowke JH, Gamulin M, Usmani N, Claessens F, Castelao JE, Petrovics G, Parent MÉ, Hu JJ, Zheng W; Profile Study Steering Committee; UKGPCS collaborators; Kote-Jarai Z, Eeles RA; PRACTICAL Consortium; VA Million Veteran Program; Maxwell KN, Vassy JL, Seibert TM.: Germline polygenic score for prostate cancer aggressiveness. medRxiv Page: 2026.05.07.26352488, May 2026 Notes: doi: 10.64898/2026.05.07.26352488.
